Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7752W HIGH $7.18
Volume
35.50 M
Value Traded
46.11 M
Short % Float
37.13%
-8.79%Week
+36.25%1 Month
+32.12%3 Month
+27.49%6 Month
-87.08%5 Year
-89.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.33 B
EPS (TTM)
-0.97
P/E Ratio
-
Ent. Value
1.79 B
Total Shares
535.28 M
Float Shares
481.41 M
Insiders
10.23%
Institutions
62.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RXRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Recursion Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Recursion Pharmaceuticals, Inc.
334Total events
21Upcoming
85Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Genentech exercises first Validated Target Option, advancing first neuroscience target into early discovery program
neurosciencesource ↗
●Enrollment UpdateREC-4881Trial
TUPELO now enrolling patients ages 18 and older, plus alternative dosing cohort
Familial Adenomatous Polyposis (FAP)source ↗
●Management ChangeCorporate
Hoifung Poon appointed Chief AI Officer; Donovan Chin appointed SVP Drug Design
●Runway Guidance UpdateCorporate
Reduced 2026 cash operating expense guidance to <$375 million
●FDA Feedback ReceivedREC-4881FDA Meeting
Discussions with FDA initiated in 1H26 to define registrational path
Familial Adenomatous Polyposis (FAP)source ↗
◆Management ChangeCorporate
Vicki Goodman, M.D. appointed as Chief Medical Officer effective April 6, 2026
◆Milestone PaymentREV102Corporate
Rallybio eligible for $5M milestone payment upon initiation of dosing in Phase 1 study
hypophosphatasiasource ↗
▲First Patient DosedREC-4539Trial
First patient dosed in Phase 1 ENLYGHT study of REC-4539 (LSD1 inhibitor) in solid tumors
solid tumors, including small cell lung cancer (SCLC)source ↗
◆Timing GuidanceREC-4881Presentation
Regulatory update on registrational pathway for REC-4881 expected in 2H26
familial adenomatous polyposis (FAP)source ↗
◆Timing GuidanceREC-1245Presentation
Additional Phase 1 dose escalation data expected in 2H26 (duplicate)
solid tumorssource ↗
◆Timing GuidanceREC-7735Presentation
Go/no-go decision on Phase 1 initiation for REC-7735 (PI3Kα H1047R) expected in 2H26
◆Timing GuidanceREC-102Presentation
Go/no-go decision on Phase 1 initiation expected in 2H26 (duplicate)
◆Topline ReadoutREC-3565Clinical Data
Early Phase 1 safety and PK monotherapy data for REC-3565 expected
B cell malignanciessource ↗
◆FDA Feedback ReceivedREC-4881FDA Meeting
Discussions with FDA initiated in 1H26; update to define registrational path expected in 2H26
Familial Adenomatous Polyposis (FAP)source ↗
▲Partnership / LicenseCorporate
Expanded strategic partnership with Citeline to advance AI-enabled ClinTech platform
◆Timing GuidancePresentation
Approximately 10 clinical trial readouts expected in next 18 months
◆Management ChangeCorporate
CEO transition: Najat Khan to become CEO, Chris Gibson to become Chairman effective January 1, 2026
◆Topline ReadoutREC-1245Clinical Data
Early Phase 1 safety and PK monotherapy data for REC-1245 expected
solid tumors and R/R lymphomassource ↗
◆Oral PresentationREC-4881Presentation
Webinar presenting updated safety and efficacy data from TUPELO Phase 1b/2 trial of REC-4881 in FAP
Familial Adenomatous Polyposissource ↗
▲Topline ReadoutREC-4881Clinical Data
Positive Phase 1b/2 data from TUPELO trial showing rapid and durable reductions in polyp burden at Week 25
familial adenomatous polyposis (FAP)source ↗
◆Timing GuidanceREC-3964Presentation
Expect preliminary readout by end of 2025
Recurrent Clostridioides difficile infectionsource ↗
◆Timing GuidanceREC-1245Presentation
Phase 1 data from dose-escalation expected by end of 2025
Biomarker-enriched solid tumors and lymphoma (Target RBM39)source ↗
◆Poster PresentationREC-102Presentation
Poster presentation on REC-102 at ASMBR 2025
Hypophosphatasia (HPP)source ↗
●Enrollment UpdateREC-1245Trial
DAHLIA trial enrolling select tumor types for REC-1245
Advanced solid tumorssource ↗
●Enrollment UpdateREC-617Trial
Enrollment activities initiated for REC-617 combination cohort in ovarian cancer
Platinum-resistant ovarian cancersource ↗
▲Partnership / LicenseREV102Corporate
Recursion acquires full rights to REV102 from Rallybio
hypophosphatasiasource ↗
●IND Enabling CompleteREV102Preclinical
REV102 currently in IND-enabling studies
hypophosphatasiasource ↗
▲Development Candidate NominationREC-7735Preclinical
Nominated REC-7735 as a new development candidate
▲Milestone PaymentCorporate
Achieved over $500 million in upfront and milestone payments from partners
▲Partnership / LicenseCorporate
Roche and Genentech exercised option for second neuro map (microglia map)
●IND Enabling CompleteREC-3565Preclinical
REC-3565 IND-enabling studies ongoing
B-cell malignanciessource ↗
●IND Enabling CompleteREV102Preclinical
REV102 IND-enabling studies ongoing
Hypophosphatasia (HPP)source ↗
▼Program DiscontinuationREC-4539Corporate
REC-4539 (LSD1) strategic pause to ensure competitive TPP
Solid tumors (e.g., SCLC)source ↗
▲Partnership / LicenseCorporate
Pharma partnerships with approximately $455M earned to date and potential >$20B in additional milestones
▲Platform ValidationBoltz-2Preclinical
Open-source release of Boltz-2 biomolecular foundation model
▲Milestone PaymentCorporate
Fourth milestone achieved in Sanofi collaboration, $7 million payment
Past FDA Catalysts and PDUFA Decisions
How RXRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | REC-1245 (RBM39 degrader) | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$883M
Pipeline Value
Overvalued
Valuation Signal
8
Drugs Scored
0.4x
rNPV / MCap
Top 35%
Small Cap(rank 232 of 660)
Percentile Rank
Recursion Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $1.4B risk-adjusted pipeline value, led by REC-994 in Cerebral Cavernous Malformation (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REC-994 Small moleculeCompletedNCT05085561 | Cerebral Cavernous Malformation | Phase 2 | COMPLETED | 62 | Jun 30, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every RXRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REC-1245 | solid tumors | Phase 1/2 | 2026-05-06 | REC-1245 was well-tolerated across select solid tumors(n=16); No dose-limiting toxicities (DLTs) have been observed to date; the maximum tolerated dose has not yet been reached; The majority of TRAEs were Grade 1 or 2; most common GI-related events were constipation, nausea, and vomiting; Pharmacokinetic analysis demonstrates predictable, dose-dependent exposure across evaluated patientsRead More | Recursion Reports First Quarter Financial Results and Provides Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HERSHBERG ROBERTDirector | Option | 25,000 187,156 held | $2.22 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RXRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0 % | 606.00 K | 165.32 K |
RXRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RXRX ranks across every disease it competes in
Competitive Position is a premium feature
See how RXRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRXRX News
RXRXRecursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion reported its second quarter financial results, highlighting significant advancements in its drug discovery platform and collaborations with Genentech and Sanofi. The company is progressing with its neuroscience target and has reduced its cash operating expense guidance for 2026. Despite a net loss, the collaboration with Genentech marks a pivotal point in uncovering novel therapeutic opportunities.
Read more →RXRXRecursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX) has announced its participation in two upcoming investor conferences: the Bank of America 2026 SMID Cap Executive Insights Event on August 11, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is recognized for its advanced AI-driven drug discovery platform and diverse investigational medicines portfolio.
Read more →RXRX▲ +6%on this newsshared move
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion (Nasdaq: RXRX) announced the approval of inducement RSU awards for 24 new employees, totaling 3,234,866 shares. This grant is part of the company's 2024 Inducement Equity Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, promoting employee retention and engagement.
Read more →RXRXRecursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion, a clinical stage TechBio company, is scheduled to host a public earnings call on August 5th, 2026, at 8:00 am ET. During this call, the company will provide updates on its business and financial results. This engagement reflects Recursion's commitment to transparency with its stakeholders.
Read more →RXRXRecursion To Participate In Upcoming Investor Conferences
Recursion To Participate In Upcoming Investor Conferences
Read more →RXRXRecursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Read more →RXRXRecursion Reports First Quarter Financial Results and Provides Business Update
Recursion Pharmaceuticals (RXRX) reported strong progress in its clinical pipeline during Q1 2026, achieving key milestones across various programs. Notably, REC-1245 showed promising safety and pharmacokinetics in solid tumors, while REC-4881 exhibited significant efficacy in Phase 2 trials. The company continues to maintain a solid cash position, projecting operational sustainability into early 2028.
Read more →RXRXRecursion Announces Board Transition
Recursion has announced that Chris Gibson, Ph.D., will step down from the Board of Directors but will serve as an advisor. CEO Najat Khan emphasized the company's commitment to long-term value creation and expressed optimism about future developments. Recursion is focused on advancing its investigational medicines across various therapeutic areas using its AI-powered platform. The organization's infrastructure supports its mission to translate complex science into effective therapies.
Read more →RXRXRecursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Recursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Read more →RXRX▲ +8.1%on this news
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Recursion has announced an expansion of its strategic partnership with Citeline, aiming to enhance its AI-enabled ClinTech platform. This collaboration integrates Citeline’s real-world data capabilities, supporting more precise trial designs and improved decision-making in drug development. The CEO of Recursion noted that this partnership has already led to significant improvements in enrollment rates for clinical trials. The overall goal is to create a more connected and patient-centered biopharmaceutical ecosystem.
Read more →RXRXRecursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Recursion has appointed Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026. She succeeds Dr. David Mauro, who has served in the role for three years. Dr. Goodman brings over two decades of experience in oncology and drug development, which is expected to significantly benefit Recursion's clinical programs and pipeline advancements.
Read more →RXRX▲ +6.8%on this news
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Recursion (NASDAQ: RXRX) reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical programs and partnerships. The company achieved over $500 million in milestone payments and reduced its cash operating expenses to approximately $400 million. CEO Najat Khan emphasized the maturity of their AI-driven drug discovery platform, which is expected to drive future growth.
Read more →RXRXRecursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
Recursion (RXRX) will participate in a Lightning Talk at the NVIDIA GTC AI Conference, showcasing advancements in AI and automation in drug discovery. CEO Ira Hoffman will discuss the collaboration with HighRes Biosolutions to develop self-driving labs. This initiative aims to revolutionize drug discovery processes through advanced technologies and massive data generation.
Read more →RXRXRecursion To Report Fourth Quarter And Full Year 2025 Business Updates And Financial Results On February 25
Recursion To Report Fourth Quarter And Full Year 2025 Business Updates And Financial Results On February 25
Read more →RXRXRecursion To Present At 44th Annual J P Morgan Healthcare Conference
Recursion To Present At 44th Annual J P Morgan Healthcare Conference
Read more →RXRXPositive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Recursion announced positive Phase 1b/2 results from the TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial showed a median reduction of 43% in polyp burden after 12 weeks, with 82% of patients maintaining reductions at Week 25. This marks a significant advancement in treatment options for FAP, a condition with no approved therapies.
Read more →RXRX▼ -5.8%on this news
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
Recursion announced a webinar scheduled for December 8, 2025, to present new clinical data from the TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP). The webinar will focus on updated safety and efficacy results. This event will be streamed live on multiple platforms, showcasing Recursion's commitment to transparency in clinical research.
Read more →About Recursion Pharmaceuticals, Inc.
Headquarters41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
BIOPHARMAWATCH ELITE PLUS
Trade the next RXRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime